Akebia ustekinumab patent?

“Akebia” and “ustekinumab” are usually two separate things:

• Ustekinumab (Stelara) is a biologic antibody for immune-mediated diseases (e.g., psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, etc.).
• Akebia Therapeutics is a company best known for roxadustat (an anemia drug for CKD), not for ustekinumab.

So I want to make sure I answer the right question. When you say “Akebia ustekinumab patent”, do you mean:

1. Which patents does Akebia hold on ustekinumab?
2. Whether Akebia is trying to use/claim ustekinumab under patent litigation or ownership?
3. Patent status/expiry for ustekinumab (Stelara) in general?

If you mean “patent status for ustekinumab (Stelara)”

Ustekinumab’s key patents are held by Janssen Biotech (and related entities). Exact expiry depends on country and on which patent family (composition, formulation, method of use, biologic process, extensions). Also, biologics often have a mix of patents with different expiration dates.

Quick next step (so I can give you the right answer)

Tell me:

• Country/region (US, EP/UK, Canada, etc.)
• Whether you want expiry date or what patents are listed
• Any details like a patent number, indication (e.g., psoriasis vs Crohn’s), or the company name you saw (Akebia vs Janssen)

Reply with those and I’ll narrow down the relevant patent(s) and likely timeline.